MedPath

Shanghai Institute of Hypertension

🇨🇳China
Ownership
-
Established
1958-01-01
Employees
-
Market Cap
-
Website
http://www.china-sih.com/

Clinical Trials

6

Active:0
Completed:1

Trial Phases

2 Phases

Phase 4:3
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 4
3 (60.0%)
Not Applicable
2 (40.0%)

Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension

Not Applicable
Not yet recruiting
Conditions
Chronic Kidney Disease(CKD)
Nocturnal Hypertension
Interventions
Drug: Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine
Drug: Placebo-controlled group
First Posted Date
2025-01-17
Last Posted Date
2025-01-17
Lead Sponsor
Shanghai Institute of Hypertension
Target Recruit Count
200
Registration Number
NCT06780865

Home Blood Pressure Intervention in the Community Trial

Not Applicable
Recruiting
Conditions
Home Blood Pressure
Interventions
Drug: Intensive Home BP control
Drug: Standard Home BP control
First Posted Date
2023-05-15
Last Posted Date
2025-01-06
Lead Sponsor
Shanghai Institute of Hypertension
Target Recruit Count
10000
Registration Number
NCT05858944
Locations
🇨🇳

Community hospitals, Shanghai, Shanghai, China

Registry Study on "Control Nocturnal Hypertension to Reach the Target "

Recruiting
Conditions
Nocturnal Hypertension
First Posted Date
2019-10-24
Last Posted Date
2025-01-06
Lead Sponsor
Shanghai Institute of Hypertension
Target Recruit Count
4500
Registration Number
NCT04137549
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Placebo of Gastrodia and Uncaria granule
First Posted Date
2019-07-29
Last Posted Date
2025-01-07
Lead Sponsor
Shanghai Institute of Hypertension
Target Recruit Count
605
Registration Number
NCT04035824
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension

Phase 4
Conditions
Masked Hypertension
Interventions
First Posted Date
2014-06-05
Last Posted Date
2014-06-06
Lead Sponsor
Shanghai Institute of Hypertension
Target Recruit Count
400
Registration Number
NCT02156024
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.